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Abstract
Objective To assess the clinical value of multi-phase,
contrast-enhanced DOPA-PET/CT with emphasis on the
diagnostic CT component in patients with neuroendocrine
tumours (NET).
Methods Sixty-five patients with NET underwent DOPA-
cePET/CT. The DOPA-PET, multi-phase CT and combined
DOPA cePET/CT data were evaluated and diagnostic
accuracies compared. The value of ceCT in DOPA cePET/
CT concerning lesion detection and therapeutic impact was
evaluated. Sensitivities, specificities and accuracies were
calculated. Histopathology and clinical follow-up served as
the standard of reference. Differences were tested for
statistical significance by McNemar’s test.
Results In 40 patients metastatic and/or primary tumour
lesions were detected. Lesion-based analysis for the DOPA-
PET showed sensitivity, specificity and accuracy of 66%,
100% and 67%, for the ceCT data 85%, 71% and 85%, and
for the combined DOPA cePET/CT data 97%, 71% and
96%. DOPA cePET/CT was significantly more accurate
compared with dual-phase CT (p<0.05) and PET alone (p<
0.05). Additional lesion detection was based on ceCT in 12
patients; three patients underwent significant therapeutic
changes based on the ceCT findings.
Conclusion DOPA cePET/CT was significantly more accu-
rate than DOPA-PET alone and ceCT alone. The CT
component itself had a diagnostic impact in a small
percentage but contributed to the therapeutic strategies in
selected patients.
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Introduction
Neuroendocrine tumours (NET) are a heterogeneous group
of neoplasms with an incidence of 100,000 per year in the
U.S. and thus, represent a larger group of cancer patients
than pancreatic cancer, gastric cancer, oesophageal cancer
or hepatobiliary cancer [1–4]. The course of the disease
depends on time of diagnosis, clinical staging, histopathol-
ogy, grading and consecutive therapy. The time point of
diagnosis is usually late after the disease onset, because a
significant number of patients are asymptomatic for a long
time [2] . Therefore, accurate and early diagnosis are crucial
for the prognosis of these patients. Generally, staging
includes morphological imaging techniques (computed
tomography (CT) and/or magnetic resonance imaging
(MRI)) to provide anatomical information about local-
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isation of the primary tumour as well as number and
localisation of metastases. In CT, an arterial contrast phase
as well as a portal-venous phase (or late venous phase) is
needed for localisation and characterisation of NET. In
addition, standard somatostatin receptor scintigraphy (SRS)
is generally used to localise and characterise the NET.
However, a significant rate of false negative results with
sensitivities ranging between 50% and 78%, have been
reported [2, 5–9]. Positron emission tomography (PET)
using the catecholamine precursor 6-(fluoride-18) fluoro-
dopa (F18-DOPA) has been proposed as an alternative
imaging option for NET and has already been shown to
have a significant therapeutic impact in selected patient
populations with NETs [7, 10–12]. Combined FDG-PET/
CT is already known to overcome the drawbacks of CT
alone and PET alone in a variety of tumours [13–16]. So
far, there has been no broad experience concerning the
diagnostic accuracy of a combined, triple-phase contrast-
enhanced DOPA-PET/CT (DOPA cePET/CT) in the NETs
available and the particular additional value concerning
diagnosis and therapy of NETs of the ceCT component of
such a combined protocol has not been evaluated.
Thus, the aim of our study was to prospectively evaluate:
1. the overall diagnostic accuracy of DOPA cePET/CT,
multiphase CT (ceCT) and PET only in a lesion-based,
region-based and patient-based analyses in a heterogeneous
patient population with NET and 2. to evaluate the
incremental diagnostic and therapeutic value of ceCT in
such a combined protocol.
Materials and methods
Patients
Sixty-five consecutive patients (mean age: 56 years,
range: 16–80 years, 35 female, 30 male) were prospec-
tively included between November 2006 and January
2009 in this study. The median follow-up time was
12 months (range 2–26 months, mean follow-up time:
13 months). Patients with suspicion of newly occurred
neuroendocrine tumours based on clinical symptoms,
laboratory findings or previous imaging (30 patients)
and patients already known to have a neuroendocrine
tumour and who were operated on or treated with
systemic therapy (35 patients) were included in this
study. Patients were included with no further selection
based on the time point of their referral. Patients with
severe claustrophobia and pregnant women were exclud-
ed. The study was performed in accordance with the
regulations of the local institutional review board and
ethics committee. Written informed consent was obtained
from all patients before the DOPA cePET/CT-study.
PET/CT imaging
All data were acquired on a combined PET/CT in-line
system (Discovery VCT, GE Healthcare, Milwaukee, WI,
USA). This dedicated system integrates full-ring PET
system with multislice helical 64-slice CT and permits the
acquisition of co-registered CT and PET images in one
imaging procedure.
PET/CT imaging was started 45 min after the injection
of a standard dose of 200–220 MBq F18-DOPA. In
addition, 500 ml of tap water was given to the patient
10 min before imaging. All patients initially underwent
CT without intravenous contrast medium. This was
acquired with the following parameters: 80 mA, 140 kV,
0.5-second tube rotation, 4.25-mm section thickness.
Imaging extendedfrom the vertex to the upper thighs.
Directly after this unenhanced CT data had been acquired,
the emission PET Data acquisition was initiated with
an acquisition time of 2 min per bed position. Then,
intravenous contrast medium was administered by inject-
ing a total dose of 90–120 ml Ultravist 300 (Bayer
Schering Pharma) with a flow of 4 ml/sec for an arterially
contrast-enhanced CT for the abdomen and/or thorax and
abdomen.
After a delay of 70 seconds, another ceCT (120 kV,
dose-modulated tube current up to 700 mA, 2.5 mm, pitch
1.375:1, 13.75 mm/rotation speed) was applied to ensure a
portal venous phase. The initially acquired non-enhanced
low-dose CT data (3.75-mm slices) were used for attenu-
ation correction, and images were reconstructed by using a
standard fully 3 D-iterative algorithm (ordered subset
expectation maximisation, OSEM). For image co-
registration and analysis, all reconstructed images were
then transferred to a commercially available workstation
(Advantage Workstation, 4.4, GE Healthcare, Milwaukee,
WI, USA), where image data can be evaluated in all three
planes as single procedures (multi-phase CT-only, PET-
only) and in a co-registered mode (co-registered PET/CT).
Thus, all tomographic imaging techniques (multi-phase CT
only, PET only and DOPA cePET/CT) were derived from
the same imaging procedure.
Imaging analysis
The participating readers were informed about the patient-
specific clinical background (e.g. suspected diagnosis), but
were blinded to the results of the other imaging procedures
and the results of the clinical investigation (e.g. endoscopy,
urine analysis). PET only and DOPA cePET/CT images
were evaluated qualitatively for areas of focally increased
DOPA metabolism above the surrounding tissue level. No
quantitative assessment (e.g. Standard Uptake Value) was
used for further lesion characterisation. On combined
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DOPA-cePET/CT, lesion detection (primary tumour, lymph
node metastases, distant metastases) was based on the
detection of soft tissue masses with arterial and/or venous
contrast enhancement in conjunction with increased F18-
DOPA activity. Lymph nodes on combined DOPA cePET/
CT imaging were assessed for metastatic spread based on
increased F18-DOPA activity and independent of their size.
On PET only imaging, lesion detection and character-
isation were derived from the same criteria as on DOPA
cePET/CT-imaging, however, without the evaluation of the
CT component.
On multi-phase CT images (ceCT), detection of soft
tissue masses with arterial and/or venous contrast enhance-
ment characterised malignancy. Lymph node assessment on
CT only imaging was based on lesion size (threshold 1-cm
short-axis diameter) [17]. Central necrosis was defined as a
sign of malignancy as well, independent of lymph node
size. A fatty hilum as well as calcifications were used as
benign criteria on ceCT.
All evaluations were performed on a lesion-based analysis,
a region-based analysis and a patient-based analysis.
Standard of reference (including SRS imaging)
In all patients, histopathological evaluation (surgical
specimen, biopsy) as well as the clinical course contain-
ing all available clinical data (physical examination,
further imaging including SRS imaging, laboratory
findings) served as the standard of reference. In 36
patients histopathological verification of at least one
lesion was available based on surgical procedures after
DOPA imaging (17 patients), the remaining patients had
biopsy or surgical procedures before DOPA-PET/CT
imaging. The remaining four patients (of 40 patients
with lesions, see “Results”) did not receive histopatho-
logical evaluation for various reasons (e.g. typical labora-
tory findings and concomitant typical imaging findings,
typical imaging findings but patient refused to have the
biopsy, typical imaging findings but patient was not
operated on because of good clinical condition and age,
previous neuroendocrine tumour with recurrent rise of
tumour markers and concomitant imaging findings). In the
remaining patient population (no pathological findings in
DOPA-PET/CT, see “Results” below), the clinical course
containing the above-mentioned criteria and eight biopsy
procedures served as the standard of reference. Mean
follow-up time was 13 months (range 2–26 months).
In 49 patients, whole-body planar SRS imaging contain-
ing anterior and posterior views was performed 5 h and
24–30 h after the injection of 150–200 MBq of In-111–
Octreotide. Scintigraphy was performed on different sys-
tems with a medium energy collimator. Patients underwent
SPECT imaging in the area of interest in the event of
suspicious findings on planar imaging (45 patients). Four
patients received no additional SRS imaging because the
diagnosis could be clearly made on planar imaging and the
nuclear medicine physician responsible decided to skip
the additional SPECT procedure.
Statistical analysis
The primary endpoint of the study was the correct lesion
detection and characterisation using CT only and PET only
in comparison to combined DOPA-cePET/CT. Differences
in the assessment of lesion detection between the different
imaging procedures were tested for significance by
McNemar’s test (exact). A p value <0.05 was considered
significant. Confidence intervals for the accuracy were
calculated with a two-sided single proportion test. Sensi-
tivities, specificities and accuracies (with exact 95%
confidence intervals) for all techniques were determined
using histology and/or clinical follow-up as the standard of
reference. Statistical analyses were performed with Micro-
soft Excel and MedCalc Software (Version 11.0.1.0
Broekstraat 52, 9030 Mariakerke, Belgium).
Results
Patients
All of the 65 patients evaluated had sufficient follow-up.
Forty-nine patients had SRS imaging. In 20 patients, no
suspicious findings were found with any of the imaging
techniques under evaluation. In all 20 patients, no other
imaging technique detected a neuroendocrine tumour
during the clinical follow-up. In the remaining 45 patients,
227 neuroendocrine tumours/lesions were detected. The
main body compartments affected were: liver (124 lesions),
other intraperitoneal/retroperitoneal abdominal lesion (42
lesions), skeleton (27 lesions) thorax/neck (26 lesions) and
the small bowel (eight lesions). In 36 patients, histopatho-
logical verification was available. Overall, 11 (17%)
patients had (or had previously during clinical work-up) a
neuroendocrine tumour (carcinoid) of the pancreas, 10
(15%) patients had a tumour (carcinoid/neuroendocrine
carcinoma) of the small bowel, 5 (8%) had pheochromo-
cytomas, 4 (6%) had medullary thyroid carcinomas, 2 (4%)
had other paragangliomas, in 2 (4%) patients we detected
only carcinoid metastases to the liver without a detectable
primary, one patient had a neuroendocrine carcinoma of the
lung and one patient had a neuroendocrine tumour of the
stomach. Overall, 23 patients had metastatic lesions of
different NETs to the liver. In eight patients, the primary
tumour (6 small bowel lesions, two pancreatic lesions) were
detected in the DOPA-cePET/CT, 5 of those primary
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tumours were previously unknown (Fig. 1). In one patient
(with primary NET of the pancreatic head), an additional
breast cancer with slight DOPA activity was detected and
confirmed by mammography and histopathology.
Overall diagnostic accuracy
Overall, 227 lesions were detected. Of these, 158, 193 and
218 lesions were correctly evaluated (true positive and true
negative) by DOPA-PET, ceCT and combined cePET/CT.
Seventy-four lesions, 34 lesions and nine lesions were
evaluated incorrectly (false negative and false positive) on
DOPA-PET, ceCT and combined DOPA-cePET/CT.
Lesion-, region- and patient-based analyses for DOPA
PET only, ceCT and combined DOPA-cePET/CT are shown
in Tables 1 and 2. Overall, the DOPA-PET only shows
moderate sensitivity and accuracy. On the other hand, it
provides an optimal specificity.
Conversely, ceCT had higher sensitivity but lower
specificity than DOPA-PET. These results are mainly based
on two false positive lesions (two small liver lesions with
arterial enhancement) which were falsely evaluated as
metastases. In one patient the combined DOPA-cePET/CT
was falsely negative—a NET of the pancreatic head was not
detectable and was only visible on MRI (Fig. 2). Overall
ceCT was found to be statistically more accurate than
DOPA PET only (p<0.05, lesion-based analysis) while
combined DOPA-cePET/CT was statistically more accurate
than ceCT (p<0.05) and DOPA PET only (p<0.05).
Incremental diagnostic and therapeutic value of the CT
component
DOPA-cePET/CT was diagnostically superior to PET only
based on the multi-phase CT component in 12 patients. One
of these patients was post-liver transplant, and the ce-CT
component detected DOPA-negative liver and lung metas-
tases. However, there was no change in therapy because the
patient showed stable disease. In one patient post-
sandostatin-therapy, the ce-CT component detected multiple
liver metastases. Also here, no change in therapy was
induced.
Fig. 1 a MIP, b and d axial contrast-enhanced CT, c and e combined
DOPA-cePET/CT. Seventy-five-year-old woman with known liver
metastases of a well-differentiated neuroendocrine carcinoma. A
mesenteric lymph node was known from serial CTs and SRS imaging
(a arrow Nr. 1, b big white arrow). A primary tumour had so far not
been detected on previous morphological imaging and SRS imaging.
On combined DOPA-cePET/CT, three primary tumours were detected
within the jejunum. One primary tumour was detected directly
ventrally within the jejunal wall (a arrow Nr. 2, b small white arrow,
c corresponding DOPA-cePET/CT), another was detected more
distally in the jejunal wall (a arrow Nr. 3, d white arrow, e
corresponding DOPA -cePET/CT) and the last primary was again
detected more distally in the jejunum (a arrow Nr. 4, no axial slices
shown)
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In another patient, a DOPA-negative, largely cystic
pancreatic tumour was detected. The patient was operated
based on the CT findings and an adeno-carcinoma was
identified by histopathological evaluation. In one patient, the
ce-CT detected very small recurrent liver metastases 7 years
after surgery of a carcinoid tumour. Imaging findings did not
lead to a therapy change, because the lesions were very small.
In one patient a small neuroendocrine tumour of the jejunum
was DOPA-negative and was only detected by its arterial
enhancement on ce-CT (Fig. 3). The patients underwent
surgery of the primary tumour. In one patient, the CT
component detected the primary tumour, concurrent lymph
nodes and liver metastases of a known pancreatic NET. In
another patient, the CT component identified the DOPA-
negative liver and bone metastases of an unknown, as yet
undiscovered primary NET. In both patients, previous
systemic therapy was not changed because the imaging
confirmed the suspected sites of disease. Lastly, in one
patient, small (DOPA-negative) liver metastases were sug-
gested based on their arterial enhancement. The patient
underwent surgery and histopathology revealed small ade-
nomas with ectatic feeding vessels. In four patients, the ce-
CT component detected just additional metastases compared
with the already detected DOPA-positive metastases (liver
metastases, lymph node metastases, bone metastases). These
additional findings led to a therapy change from previously
intended surgical therapy to a systemic therapy approach in
one patient.
Discussion
Comparison with conventional imaging
Several studies already investigated the usefulness of
DOPA-PET and PET/CT concerning the diagnostic accura-
DOPA-PET Lesion-based analysis Patient-based analysis
Sensitivity (95%-CI) 66% (60–72%) 82% (66–92%)
Specificity (95%-CI) 100% (63–100%) 100% (87–100%)
Accuracy (95%-CI) 67% (61–73%) 89% (79–96%)
Mutli-phase CT
Sensitivity (95%-CI) 85% (80–90%) 93% (80–98%)
Specificity (95%-CI) 71% (29–96%) 100% (86–100%)
Accuracy (95%-CI) 85% (80–89%) 95% (87–99%)
Combined DOPA-cePET/CT
Sensitivity (95%-CI) 97% (94–99%) 98% (87–100%)
Specificity (95%-CI) 71% (29–96%) 100% (86–100%)
Accuracy (95%-CI) 96% (93–98%) 98% (92–100%)
Table 1 shows the lesion-based
and patient-based sensitivities,
specificities, accuracies and
corresponding 95% confidence
intervals of the DOPA-PET,
multi-phase CT and combined
DOPA-cePET/CT evaluation
Table 2 shows the region-based sensitivities, specificities, accuracies and corresponding 95% confidence intervals of the DOPA-PET, multi-
phase CT and combined DOPA-cePET/CT evaluation
DOPA-PET Liver Abdominal lesions Thorax/neck lesions Small bowel Bone
Sensitivity (95% CI) 63% (54–71%) 77% (6189%) 64% (41–83%) 88% (47–100%) 59% (38–78%)
Specificity (95% CI) 100% (16–100%) 100% (16–100%) 100% (40–100%) n/a n/a
Accuracy (95% CI) 63% (54–72%) 78% (62–89%) 69% (48–86%) 88% (47–100%) 59% (39–78%)
Multi-phase CT
Sensitivity (95% CI) 90% (83–95%) 95% (83–99%) 73% (50–89%) 50% (16–84%) 70% (50–86%)
Specificity (95% CI) 0% (0–84%) 100% (3–100%) 100% (40–100%) n/a n/a
Accuracy (95% CI) 89% (82–94%) 95% (83–99%) 77% (56–91%) 50% (16–84%) 70% (50–86%)
Combined DOPA-cePET/CT
Sensitivity (95% CI) 96% (91–99%) 98% (87–100%) 100% (85–100%) 100% (63–100%) 96% (81–99%)
Specificity (95% CI) 0% (0–84%) 100% (3–100%) 100% (40–100%) n/a n/a
Accuracy (95% CI) 94% (89–98%) 98% (87–100%) 100% (87–100%) 100% (63–100%) 96% (81–100%)
Liver only liver lesions were counted and evaluated, Abdominal Lesions other abdominal (other than liver or small bowel) soft tissue/organ lesions
and lymph nodes were counted and evaluated, Thorax/Neck Lesions soft tissue/organ (pulmonary lesions and lymph nodes were counted and
evaluated, Small Bowel only lesions of the small bowel were counted and evaluated, Bone bone lesions within the field-of-view (FOV head to the
upper thighs) were counted and evaluated, n/a not applicable (no true negatives, no false positives in this category)
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Fig. 2 a contrast-enhanced (arterial phase) axial CT, b contrast-
enhanced (venous phase) axial CT, c combined DOPA-cePET/CT, d
corresponding T1-weighted, post-gadolinium, fat-saturated, axial MRI,
e T2-weighted, fat-saturated, axial MRI. Seventy-two-year-old woman
with clinical signs of a neuroendocrine tumour and follow-up after
lung tumour surgery. A suspect lesion of the pancreas could not be
detected, neither on dual-phase CT (a and b), nor on combined DOPA-
cePET/CT (c). Only the corresponding MRI showed multifocal lesions
within the pancreatic head (see arrows in d and e). Lesions were
surgically removed and confirmed as well-differentiated, multifocal,
neuroendocrine carcinoma
Fig. 3 a contrast-enhanced
(arterial phase) axial CT, b
corresponding DOPA-PET/CT,
c corresponding MIP image.
Sixty-three-year-old male
patient with clinical signs of a
carcinoid. The arterial phase
of the contrast-enhanced DOPA-
cePET/CT showed a focal, arte-
rially enhancing lesion of the
jejunum (white arrow, a), how-
ever, without DOPA-activity (b).
Corresponding MIP image (c)
also showed no pathological
DOPA activity in this patient.
The tumour was diagnosed
solely on the ceCT component
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cy in a variety of NETs and its subtypes [6, 18–23]. The
diagnostic superiority of DOPA-PET over conventional
SRS imaging has been demonstrated in several studies [7,
24, 25]. While Hoegerle et al. reported in a small patient
population an overall sensitivity of 65% for DOPA-PET in
a lesion-based analysis, Koopmans and co-workers found
lesion-based sensitivities ranging between 95% and 100%
[6, 7]. Moreover, DOPA-imaging proved to be useful in
patients in whom SRS imaging was negative [26].
Overall diagnostic value of DOPA-PET/CT
and comparisons with other tracers
DOPA-PET and PET/CT already demonstrated high diag-
nostic values when evaluating heterogeneous patient
populations and several subtypes of NETs [6, 7, 25].
Similar results concerning region-based analysis were
found e.g. by Becherer et al. [25], who reported sensitivities
between 81% and 100% and specificities between 85% and
100%, which compare well with our results. DOPA-PET
and PET/CT were already compared with several other PET
tracers (DOTA-TOC/NOC/TATE). Putzer and co-workers
evaluated DOTA-TOC vs. DOPA-PET and found sensitiv-
ity of 64%, which is somewhat lower than our results and
specificity of 100% for both techniques on a patient-based
analysis [27]. However, 68 Ga-DOTA-TOC PET found
more lesions (208 malignant lesions vs. 86 lesions) than
DOPA-PET.
Ambrosini et al. also found a slight trend of superiority
of 68 Ga-DOTA-NOC over DOPA-PET concerning lesion
detection [24]. In another study evaluating DOTA-TATE
versus DOPA-PET in well-differentiated metastatic neuro-
endocrine tumours, Haug et al. found sensitivities of 96%
for 68 Ga-DOTA-TATE versus 56% for DOPA-PET [28].
The reason for the somewhat lower results might be that
only well-differentiated neuroendocrine tumours were
evaluated.
Incremental clinical value of CT
To our knowledge, this is the first study to investigate an
integrated approach of a combined DOPA-cePET/CT with
emphasis on the value of the CT component.
Koopmans et al. showed that a corresponding CT
component can add significant information for the diagno-
sis, leading to increased detection rates in most of the body
regions. In our study, adequate multi-phase CT in combined
DOPA-cePET/CT added significant information to the
diagnostic sensitivity compared with DOPA-PET but, based
on the above mentioned false positive lesions, at the cost of
decreased specificity.
Koopmans et al. investigated in another study the
usefulness of DOPA-PET and CT in carcinoids vs. its
usefulness in islet cell carcinomas [12]. In carcinoid tumour
patients, per-patient analysis showed sensitivities for DOPA-
PET and CT of 96% each. The per-lesion analysis revealed
sensitivities for DOPA PET, DOPA PET/CT and CT alone of
87%, 98% and 63%. While the results for DOPA- PET/CT
again compare very well with our results, we found lower
values for the DOPA-PET, but higher values for the CT
component. The reasons are probably that we investigated an
inhomogeneous patient population compared to patients
having only carcinoids. The lower results of CT are
explainable by the used one-phase contrast CT, while we
used a multi-phase CT. We found one large study that
investigated PET in NET vs. adequately performed multi-
phase CT, but the PET was conducted with DOTA-TOC and
not DOPA [29]. This study comprised (like ours) a mixed
patient population. This study found somewhat lower values
for sensitivity, specificity and accuracy at least for the
patient-based analysis. Unlike our study, the CT was
conducted separately and was co-registered afterwards to
the PET which might explain some of the differences.
Several studies already indicated the therapeutic useful-
ness of DOPA-PET and PET/CT compared with previous
conventional imaging [30–32]. Ambrosini and co-workers
e.g. found a significant impact in therapy management
induced by DOPA-PET/CT compared with conventional
imaging. However, neither contrast-enhanced PET/CT was
evaluated nor the diagnostic impact of the CT component
itself. Montravers et al. demonstrated that DOPA-PET can
have a significant therapeutic impact on patient manage-
ment but here again, the PET component was evaluated
concerning the therapeutic impact.
At first glance, the therapeutic impact of the ceCT
component seems rather small in our study because most of
the lesions are certainly detected by the DOPA component
of PET/CT and ceCT made its major impact in DOPA-
negative lesions. There are two aspects to consider: almost
every patient who is a candidate for curative or palliative
surgery will receive an adequate morphological imaging
procedure (most cases: ce-CT, less often MRI) before the
surgical procedure. Thus, an integrated “one-stop-shop”
imaging approach is certainly desirable for the patients. In
these cases, exact anatomical localisation is important,
because neuroendocrine tumours of the GI tract in
particular can be very small [33]. The second aspect is
follow-up in patients after systemic therapy. Our study
showed that the CT component in DOPA-negative lesions
(after therapy) can add significant diagnostic and therapeu-
tic value to the PET/CT procedure.
Limitations/controversies
Our study has several limitations. Histopathological verifi-
cation was obtained in a significant number but not in all
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patients after the DOPA-cePET/CT. In several patients no
tumour was found and several patients already had an
advanced stage with clear clinical signs and were therefore
treated systemically without further/additional verification.
We did not pre-treat our patients with Carbidopa. Although
it has been shown that such pre-treatment can increase the
DOPA uptake in tumours/lesions, there is no comparison
between pre-treated and non-pre-treated patients available
in the current literature [34].
Conclusion
Combined DOPA-cePET/CT proved to be significantly
superior to DOPA-PET and multi-phase CT concerning
diagnostic accuracy. While the DOPA-PET showed high
specificities, the multi-phase CT component added sensi-
tivity in lesion detection and had therapeutic impact
especially in DOP-negative lesions. Overall, combined
DOPA-cePET/CT seems to be a robust “one-stop-shop”
approach, and has the potential to improve cancer diag-
nostics in patients with a variety of neuroendocrine
tumours.
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